RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with chronic Pseudomonas aeruginosa (Pa) colonisation.
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it will be holding a webinar for investors, analysts and media on Wednesday 31 January 2023 at 10.00 EST/15.00 GMT/16.00 CET.
The event, which will be chaired by CEO Dr Peter Jackson, will provide a deeper insight into RESP-X, the Company’s Phase II anti-virulence candidate to treat exacerbations due to chronic Pseudomonas aeruginosa (Pa) colonization in non-cystic fibrosis bronchiectasis (NCFB) patients. Speakers will include Prof. Colm Leonard, Chief Medical Officer and Dr Victoria Savage, Chief Scientific Officer. There will also be an opportunity for attendees to take part in a Q&A.
RESP-X is a first-in-class anti-virulence antibody targeting chronic Pa bacterial infections in NCFB patients. Colonisation with Pa increases the severity of NCFB, leading to recurring episodes of debilitating and life-threatening infection. There are currently up to six million NCFB patients in major global markets, of which up to 30% have chronic Pa colonisation. Despite its prevalence and severity, there are currently no approved treatments for prevention of infective exacerbations due to Pa colonisation in NCFB patients.
To register your interest for the webcast please contact [Carl Curran carl.curran@infextx.com/ Walbrook PR at
infex@walbrookpr.com/]
A recording of the presentation will be made available on the Company’s website after the event.